Table 2. Specimen type, site of collection, and microbiologic characteristics in study of carbapenem-sparing regimen for extensively drug-resistant Acinetobacter baumannii in an ICU, Beirut, Lebanon* .
| Specimens and testing |
Period 1† |
Period 2‡ |
|---|---|---|
| Specimen type, no. | ||
| Sputum | 31 | 11 |
| Blood | 0 | 3 |
| Wound site or catheter tip |
0 |
3 |
| Site of collection, no. | ||
| Intensive care unit | 21 | 12 |
| Regular floor | 10 | 5 |
| Total no. | 31 | 17 |
| Antimicrobial drug susceptibility testing by disc diffusion, % | ||
|---|---|---|
| Cefepime/ceftazidime | 0 | 64.7 |
| Piperacillin/tazobactam | 0 | 17.65 |
| Imipenem | 0 | 17.65 |
| Colistin |
100 |
100 |
| Total extensively drug-resistant | 100 | 35.3 |
| Carbapenemase genes, no. (%)§ | ||
|---|---|---|
| ESBL blaTEM-1 | 31 (100) | 17 (100) |
| blaoxa-23 | 30 (96.8) | 6 (35.3) |
| blaoxa-24 | 1 (3.2) | 5 (29.4) |
| blaoxa-23 and blaoxa-24 | 0 | 3 (17.6) |
| Sequence type, no. (%)¶ | ||
|---|---|---|
| ST2 | 29 (93.5) | 0 |
| ST699 | 1 (3.25) | 0 |
| ST627 | 1 (3.25) | 0 |
| ST25 | 0 | 10 (58.9) |
| ST99 | 0 | 1 (5.8) |
| New STs, 1200–1206 | 0 | 6 (35.3) |
*Bold indicates statistical significance. ESBL, extended-spectrum beta-lactamase; ICU, intensive care unit; MLST, multilocus sequence typing; PCR, polymerase chain reaction; ST, sequence type. †During February 1, 2016–June 30, 2016, ICU patients received colistin/carbapenem therapy for A. baumannii infections. ‡During July 1, 2016–January 31, 2017, ICU implemented carbapenem-sparing regimen for A. baumannii infections. §Determined by PCR. ¶Determined by multilocus sequence typing.